GYN ONC (Gynecologic oncology)
GOG-3112 (DS8201-772) DESTINY-Ovarian-01 - https://www.clinicaltrials.gov/study/NCT06819007?term=gog-3112&rank=1
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer.
Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy.
GOG-3127 - (TREVI-OC-01) (AZ D8991C00001) - https://www.clinicaltrials.gov/study/NCT07218809?term=d8991c00001&rank=1
Phase 3 Study of AZD5335 vs. Mirvetuximab Soravtansine in Fra-High and AZD5335 vs. Investigator’s Choice Chemotherapy in Fra-Low Advanced High-Grade Platinum-Resistant Epithelial Ovarian Cancer.
-
Jupiter Medical CenterWe want to help you! If you have questions about our services and what we can offer you and your loved ones, please reach out.
